Renaissance Group LLC Acquires 87,755 Shares of Hims & Hers Health, Inc. $HIMS

Renaissance Group LLC lifted its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 99.0% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 176,384 shares of the company’s stock after purchasing an additional 87,755 shares during the period. Renaissance Group LLC owned about 0.08% of Hims & Hers Health worth $8,793,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Nuveen LLC purchased a new stake in Hims & Hers Health during the first quarter worth $58,403,000. CloudAlpha Capital Management Limited Hong Kong purchased a new stake in shares of Hims & Hers Health during the 1st quarter worth $20,580,000. State of Michigan Retirement System grew its stake in Hims & Hers Health by 84.9% in the second quarter. State of Michigan Retirement System now owns 1,379,100 shares of the company’s stock valued at $68,748,000 after purchasing an additional 633,300 shares during the last quarter. Jump Financial LLC raised its holdings in Hims & Hers Health by 633.2% in the first quarter. Jump Financial LLC now owns 725,445 shares of the company’s stock worth $21,437,000 after purchasing an additional 626,496 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Hims & Hers Health by 19.5% during the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock valued at $71,969,000 after buying an additional 397,310 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $36.36 on Wednesday. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The stock has a 50-day moving average of $50.12 and a two-hundred day moving average of $51.42. The stock has a market cap of $8.28 billion, a P/E ratio of 67.33, a P/E/G ratio of 7.08 and a beta of 2.20. Hims & Hers Health, Inc. has a one year low of $20.02 and a one year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). The firm had revenue of $598.98 million during the quarter, compared to analysts’ expectations of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The company’s revenue for the quarter was up 49.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.32 earnings per share. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health announced that its board has approved a stock buyback program on Monday, November 17th that authorizes the company to repurchase $250.00 million in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 3% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,637 shares of the company’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $42.53, for a total value of $112,151.61. Following the sale, the insider directly owned 155,856 shares of the company’s stock, valued at approximately $6,628,555.68. This represents a 1.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Oluyemi Okupe sold 11,592 shares of Hims & Hers Health stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $57.13, for a total value of $662,250.96. Following the transaction, the chief financial officer owned 70,232 shares of the company’s stock, valued at $4,012,354.16. The trade was a 14.17% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 584,209 shares of company stock worth $31,837,916. Company insiders own 17.71% of the company’s stock.

Wall Street Analyst Weigh In

HIMS has been the subject of several recent analyst reports. Canaccord Genuity Group reiterated a “buy” rating and set a $68.00 price objective on shares of Hims & Hers Health in a research note on Friday, September 12th. Wall Street Zen lowered Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. BTIG Research reissued a “buy” rating and issued a $85.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, November 4th. Truist Financial dropped their target price on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a research note on Monday, August 18th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Two equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $45.27.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.